These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1846943)

  • 41. Apoptotic mode of cell death in substantia nigra following intranigral infusion of the parkinsonian neurotoxin, MPP+ in Sprague-Dawley rats: cellular, molecular and ultrastructural evidences.
    Banerjee R; Sreetama S; Saravanan KS; Dey SN; Mohanakumar KP
    Neurochem Res; 2007 Jul; 32(7):1238-47. PubMed ID: 17401660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Astroglial ablation prevents MPTP-induced nigrostriatal neuronal death.
    Takada M; Li ZK; Hattori T
    Brain Res; 1990 Feb; 509(1):55-61. PubMed ID: 2306638
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Involvement of iron in MPP+ toxicity in substantia nigra: protection by desferrioxamine.
    Matarredona ER; Santiago M; Cano J; Machado A
    Brain Res; 1997 Oct; 773(1-2):76-81. PubMed ID: 9409707
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
    Löschmann PA; Lange KW; Kunow M; Rettig KJ; Jähnig P; Honoré T; Turski L; Wachtel H; Jenner P; Marsden CD
    J Neural Transm Park Dis Dement Sect; 1991; 3(3):203-13. PubMed ID: 1835581
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats.
    Klockgether T; Turski L
    Ann Neurol; 1990 Oct; 28(4):539-46. PubMed ID: 2252365
    [TBL] [Abstract][Full Text] [Related]  

  • 46. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
    Greenamyre JT; O'Brien CF
    Arch Neurol; 1991 Sep; 48(9):977-81. PubMed ID: 1835370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selective stimulation of kainate but not quisqualate or NMDA receptors in substantia nigra evokes limbic motor seizures.
    Maggio R; Liminga U; Gale K
    Brain Res; 1990 Oct; 528(2):223-30. PubMed ID: 2176910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ultrastructural alterations induced by 1-methyl-4-phenylpyridinium (MPP+) in canine substantia nigra and rat mesencephalon in vitro.
    Christie-Pope BC; Burns RS; Whetsell WO
    Exp Neurol; 1989 Jun; 104(3):235-40. PubMed ID: 2785927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of ghrelin on the electrical activities of substantia nigra dopaminergic neurons treated with MPP
    Chang X; Ma Z; Shi L; Xie J
    Neurochem Int; 2020 Sep; 138():104780. PubMed ID: 32569790
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oxidative stress and microglial activation in substantia nigra following striatal MPP+.
    Miwa H; Kubo T; Morita S; Nakanishi I; Kondo T
    Neuroreport; 2004 Apr; 15(6):1039-44. PubMed ID: 15076730
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glutamatergic drugs in Parkinson's disease.
    Lange KW; Riederer P
    Life Sci; 1994; 55(25-26):2067-75. PubMed ID: 7997066
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurochemical lesioning in the rat brain with iontophoretic injection of the 1-methyl-4-phenylpyridinium ion (MPP+).
    Ter Horst GJ; Knigge MF; Van der Wal A
    Neurosci Lett; 1992 Jul; 141(2):203-7. PubMed ID: 1436635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Involvement of free radicals in MPP+ neurotoxicity against rat dopaminergic neurons in culture.
    Akaneya Y; Takahashi M; Hatanaka H
    Neurosci Lett; 1995 Jun; 193(1):53-6. PubMed ID: 7566666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of 1-methyl-4-phenylpyridinium (MPP+) on mitochondrial membrane potential in cerebellar neurons: interaction with the NMDA receptor.
    Camins A; Sureda FX; Gabriel C; Pallàs M; Escubedo E; Camarasa J
    J Neural Transm (Vienna); 1997; 104(6-7):569-77. PubMed ID: 9444558
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intracerebroventricularly-administered 1-methyl-4-phenylpyridinium ion and brain-derived neurotrophic factor affect catecholaminergic nerve terminals and neurogenesis in the hippocampus, striatum and substantia nigra.
    Chen JF; Wang M; Zhuang YH; Behnisch T
    Neural Regen Res; 2018 Apr; 13(4):717-726. PubMed ID: 29722326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quinolinic acid but not MK-801 protects the dopaminergic system from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced toxicity in goldfish retina.
    Guarnieri T; Virgili M; Carraro S; Villani L
    Neurochem Int; 1994 Jun; 24(6):559-64. PubMed ID: 7981638
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chronic exposure to Ro20-1724 protects dopaminergic neurons in vitro against the neurotoxic action of N-methyl-D-aspartate and 1-methyl-4-phenylpyridinium.
    Dickie BG; Greenfield SA
    Brain Res; 1997 Apr; 753(2):335-9. PubMed ID: 9125421
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence for retrograde axonal transport of MPP+ in the rat.
    Campbell KJ; Takada M; Hattori T
    Neurosci Lett; 1990 Oct; 118(2):151-4. PubMed ID: 2274262
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) alters hippocampal excitatory synaptic transmission by modulation of the GABAergic system.
    Huang Y; Chen J; Chen Y; Zhuang Y; Sun M; Behnisch T
    Front Cell Neurosci; 2015; 9():299. PubMed ID: 26300734
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism.
    Storey E; Hyman BT; Jenkins B; Brouillet E; Miller JM; Rosen BR; Beal MF
    J Neurochem; 1992 May; 58(5):1975-8. PubMed ID: 1560246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.